Efficacité et innocuité des thérapies ciblées combinées dans les maladies inflammatoires à médiation immunitaire : L'étude COMBIO
Dig Liver Dis. 2022 doi: 10.1016/j.dld.2022.07.012
This study suggested that COMBIO (combination of targeted therapy) appears to be effective in achieving significant and mild-to-moderate improvement in half and a quarter of patients with IMIDs, respectively. This was an ambispective study of a French cohort of patients from gastroenterology, rheumatology, and dermatology.
Overall, the safety profile presented was acceptable, and comparable to monotherapy in the short- and medium-term. COMBIO was shown to be a therapeutic option for medically refractory patients, and for patients with overlapping IMIDs. However, prospective studies are needed to validate this approach, along with long-term safety studies.
